Recently, the Gene-editing techniques such as CRISPR-Cas9 has grabbed a lot of attention after showing some promising results and are already transforming research. But there is still a long way ahead before this technique could become worthy as human therapeutics. The National Institutes of Health (NIH) has decided to boost the process by putting USD 190 million into a program to develop gene editing therapy.
Skyhawk Therapeutics grabbed a funding of USD 8 million RNA targeted therapy
Pharmaceutical startup Skyhawk Therapeutics grabbed a funding of USD 8 million to move small molecules that targets and correct the RNA expression into the clinic phases. The startup is going ahead with the same combination of executives and investors that have powered another pharma company Dragonfly Therapeutics to a deal with Celgene for the natural killer cell.
Tmunity Therapeutics successfully scored USD 100 million for advance T-cell immunotherapies
In the quest to bring better and safer T-cell Immunotherapies for both solid tumors and blood cancers, Tmunity Therapeutics and has successfully grabbed a funding of USD 100 million in series A funding. Ping An Ventures, the Parker Institute for Cancer Immunotherapy, Gilead, the University of Pennsylvania and Lilly Asia Ventures, backed the funding series.
